{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:18:54Z","timestamp":1787779134345,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010358","name":"KV Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006426","name":"Eva and Henry Fr\u00e6nkel Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilsson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010306","name":"Director Kurt B\u00f8nnelycke and Wife Mrs Grethe B\u00f8nnelyckes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"The Toyota Foundation","doi-asserted-by":"publisher","award":["KJ\/BG-9981 H"],"award-info":[{"award-number":["KJ\/BG-9981 H"]}],"id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Heart Foundation","doi-asserted-by":"publisher","award":["20-R142-A9780-22179"],"award-info":[{"award-number":["20-R142-A9780-22179"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ahj.2026.107398","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:03:55Z","timestamp":1772899435000},"page":"107398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-5736","authenticated-orcid":false,"given":"Julie H.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde MB.","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massar","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Antonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael K.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Christian","family":"Br\u00f8nd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107398_bib0001","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.ehj.2004.06.013","article-title":"The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study","volume":"25","author":"Laukkanen","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107398_bib0002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/euhj.2000.1737","article-title":"Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure","volume":"21","author":"Florea","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107398_bib0003","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cardfail.2016.01.012","article-title":"The added value of exercise variables in heart failure prognosis","volume":"22","author":"Alba","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0004","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jchf.2021.05.013","article-title":"Hemodynamic determinants of activity measured by accelerometer in patients with stable heart failure","volume":"9","author":"Omar","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ejhf.37","article-title":"Cardiorespiratory fitness and risk of heart failure: a population-based follow-up study","volume":"16","author":"Khan","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0007","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cardfail.2019.04.008","article-title":"Association between cardiorespiratory fitness and risk of heart failure: a meta-analysis","volume":"25","author":"Qiu","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0008","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.87.2.470","article-title":"Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure","volume":"87","author":"Wilson","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107398_bib0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamacardio.2023.5692","article-title":"Accelerometer-measured physical activity, sedentary time, and heart failure risk in women aged 63 to 99 years","volume":"9","author":"LaMonte","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107398_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.113.000529","article-title":"Effects of physical activity and sedentary time on the risk of heart failure","volume":"7","author":"Young","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0011","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0140-6736(16)30370-1","article-title":"Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women","volume":"388","author":"Ekelund","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107398_bib0012","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1016\/j.ijcard.2013.07.171","article-title":"Tele-accelerometry as a novel technique for assessing functional status in patients with heart failure: feasibility, reliability and patient safety","volume":"168","author":"Jehn","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2026.107398_bib0013","article-title":"Accelerometer measured physical activity and the incidence of cardiovascular disease: evidence from the UK Biobank cohort study","volume":"18","author":"Ramakrishnan","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.ahj.2026.107398_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012349","article-title":"Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials","volume":"17","author":"Docherty","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107398_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2026.107398_bib0017","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107398_bib0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00421-007-0522-8","article-title":"Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity","volume":"101","author":"Thomsen","year":"2007","journal-title":"Eur J Appl Physiol"},{"key":"10.1016\/j.ahj.2026.107398_bib0019","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0020","doi-asserted-by":"crossref","first-page":"e3335","DOI":"10.1002\/dmrr.3335","article-title":"The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: the CANA-HF study","volume":"36","author":"Carbone","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ahj.2026.107398_bib0021","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107398_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107398_bib0023","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ahj.2024.02.005","article-title":"Empagliflozin to elderly and obese patients with increased risk of developing heart failure: study protocol for the Empire Prevent trial program","volume":"271","author":"Andersen","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107398_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jchf.2013.05.008","article-title":"Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure","volume":"1","author":"Chase","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0026","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2024.08.017","article-title":"Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: determinants and relationship with patient-reported health status","volume":"278","author":"Fuchs Andersen","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107398_bib0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00005768-199805000-00021","article-title":"Calibration of the Computer Science and Applications, Inc. accelerometer","volume":"30","author":"Freedson","year":"1998","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.ahj.2026.107398_bib0028","doi-asserted-by":"crossref","first-page":"N1","DOI":"10.1088\/1361-6579\/38\/1\/N1","article-title":"Detecting free-living steps and walking bouts: validating an algorithm for macro gait analysis","volume":"38","author":"Hickey","year":"2017","journal-title":"Physiol Meas"},{"key":"10.1016\/j.ahj.2026.107398_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2026.107398_bib0030","series-title":"SD. SF-36 physical and mental health summary scales: a user\u2019s manual","author":"Ware","year":"1994"},{"key":"10.1016\/j.ahj.2026.107398_bib0031","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ahj.2026.107398_bib0032","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.ahj.2026.107398_bib0033","unstructured":"Andersen C.F., Larsen, J.H., Moeller, J.E., et al. Statistical Analysis Plan (SAP) for empagliflozin to elderly and obese patients with increased risk of developing heart failure: the Empire Prevent trial program [Statistical Analysis Plan]. 2025 [Available from: https:\/\/cdn.clinicaltrials.gov\/large-docs\/35\/NCT05084235\/SAP_000.pdf."},{"key":"10.1016\/j.ahj.2026.107398_bib0034","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO(2)): a randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2026.107398_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107398_bib0036","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1139\/cjpp-2018-0359","article-title":"Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications","volume":"96","author":"Kumar","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.ahj.2026.107398_bib0037","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1210\/jc.2018-01741","article-title":"Influence of sodium glucose cotransporter 2 inhibition on physiological adaptation to endurance exercise training","volume":"104","author":"Newman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2026.107398_bib0038","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/sms.12608","article-title":"Cardiorespiratory fitness in 16 025 adults aged 18-91 years and associations with physical activity and sitting time","volume":"26","author":"Eriksen","year":"2016","journal-title":"Scand J Med Sci Sports"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:33:52Z","timestamp":1787776432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0002870326000608"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107398","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107398"}}